Targeted therapies in myeloid leukemias.
There is still a compelling need to improve therapeutic outcome in AML. However, during the past several years our understanding of the genetic basis of AML, and the nature of the mutations that contribute to the phenotype, have been elucidated in cell culture and murine models of leukemia. The validation of various mutant leukemogenic gene products has in turn led to the development of an expanding group of molecular targeted therapies that have potential to improve the therapeutic window for treatment of AML.
Gilliland
D G
DG
Harvard Medical School, Brigham & Women's Hospital, Harvard Institute of Medicine, Boston, USA.
D006801:Humans; D007951:Leukemia, Myeloid / Q000235:genetics / Q000628:therapy*; D008232:Lymphoproliferative Disorders / Q000235:genetics / Q000628:therapy; D015337:Multicenter Studies as Topic; D009154:Mutation; D010641:Phenotype; D011519:Proto-Oncogenes / Q000235:genetics*; D015398:Signal Transduction; D014158:Transcription, Genetic